

## SEC (C165): sc-73353

### BACKGROUND

SEC (staphylococcal enterotoxin C) is a member of the staphylococcal enterotoxin family. Staphylococcal enterotoxins are superantigens secreted by *Staphylococcus aureus* that stimulate non-specific T cell proliferation. As a result of their ability to potently activate T cells, staphylococcal enterotoxins are recognized as potential drugs for cancer therapy. Further characterizing them as ideal drugs in cancer therapy, staphylococcal enterotoxins are capable of inducing apoptosis of tumor cells. Staphylococcal enterotoxins are single chain polypeptides containing one disulfide bond formed by two half cysteines in the middle of the chain. SEC is produced by methicillin-resistant strains of *S. aureus* (as well as other invasive *S. aureus* isolates) and is capable of causing severe pathologies such as toxic shock syndrome (TSS), bovine mastitis and persistent infections.

### REFERENCES

- de Carvalho Uhl, M.V., et al. 2004. Suitability of a recombinant *Staphylococcus aureus* enterotoxin C bovine variant for immunodiagnosics and therapeutic vaccine development. *Vaccine* 22: 4191-4202.
- Hu, D.L., et al. 2005. A mutant of staphylococcal enterotoxin C devoid of bacterial superantigenic activity elicits a Th2 immune response for protection against *Staphylococcus aureus* infection. *Infect. Immun.* 73: 174-180.
- Jin, Z., et al. 2005. Conjugates of group A and W135 capsular polysaccharides of *Neisseria meningitidis* bound to recombinant *Staphylococcus aureus* enterotoxin C1: preparation, physicochemical characterization, and immunological properties in mice. *Infect. Immun.* 73: 7887-7893.
- Kravitz, G.R., et al. 2005. Purpura fulminans due to *Staphylococcus aureus*. *Clin. Infect. Dis.* 40: 941-947.
- Park, Y.H., et al. 2006. Unique features of bovine lymphocytes exposed to a staphylococcal enterotoxin. *J. Vet. Sci.* 7: 233-239.
- Matsubara, K., et al. 2006. Development of serum IgM antibodies against superantigens of *Staphylococcus aureus* and *Streptococcus pyogenes* in Kawasaki disease. *Clin. Exp. Immunol.* 143: 427-434.
- Dmitrenko, O.A., et al. 2006. Detection of the genes of pyrogenic toxins of superantigens in clinical isolates of methicillin resistant *Staphylococcus aureus*. *Zh. Mikrobiol. Epidemiol. Immunobiol.* 2: 36-42.
- Pan, Y.Q., et al. 2007. Expression and bioactivity analysis of staphylococcal enterotoxin M and N. *Protein Expr. Purif.* 56: 286-292.
- Jie, K.G., et al. 2007. The pilot study of anti-tumor effects versus immunosuppression of staphylococcal enterotoxin C. *Cancer Biol. Ther.* 6: 1584-1591.

### SOURCE

SEC (C165) is a mouse monoclonal antibody raised against Enterotoxin C of *Staphylococcus aureus* origin.

### STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

### PRODUCT

Each vial contains 200 µg IgG<sub>1</sub> kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

SEC (C165) is available conjugated to agarose (sc-73353 AC), 500 µg/0.25 ml agarose in 1 ml, for IP; to HRP (sc-73353 HRP), 200 µg/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-73353 PE), fluorescein (sc-73353 FITC), Alexa Fluor® 488 (sc-73353 AF488), Alexa Fluor® 546 (sc-73353 AF546), Alexa Fluor® 594 (sc-73353 AF594) or Alexa Fluor® 647 (sc-73353 AF647), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-73353 AF680) or Alexa Fluor® 790 (sc-73353 AF790), 200 µg/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

### APPLICATIONS

SEC (C165) is recommended for detection of enterotoxin C of *Staphylococcus aureus* origin by flow cytometry (1 µg per 1 x 10<sup>6</sup> cells).

### RESEARCH USE

For research use only, not for use in diagnostic procedures.

### PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.